Patent intelligence · WO
WO 2026078619
ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION
ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION
Patent details — WO 2026078619
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Apr 16, 2026
- Expiration
- Apr 11, 2046
- Applicant
- PFIZER [US]
- CPC classes
- A61K 31/ 4166 A I, A61K 31/ 5025 A I, A61K 45/ 06 A I, A61K/314166
Quick answer
WO 2026078619 (ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION) is held by PFIZER [US]. Status: granted. Granted Apr 16, 2026. Expires Apr 11, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PFIZER [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4166 A I, A61K 31/ 5025 A I, A61K 45/ 06 A I, A61K/314166, A61K/315025, A61K/4506
More from PFIZER [US]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2026078619?
WO 2026078619 (ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION) is held by PFIZER [US]. Status: granted. Granted Apr 16, 2026. Expires Apr 11, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026078619?
PFIZER [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does WO 2026078619 expire?
Our index shows an expiration date of Apr 11, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.